Stroke Preclinical Assessment Network (SPAN) – Tacilizumab for treatment of acute ischemic stroke
卒中临床前评估网络 (SPAN) – 他珠单抗治疗急性缺血性卒中
基本信息
- 批准号:10214711
- 负责人:
- 金额:$ 50.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-15 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAcuteAdultAlteplaseAnimal ModelAnimalsAreaArteriesAtrophicBindingBlindedBlocking AntibodiesBrainBrain EdemaCaringCell DeathCerebral IschemiaCerebrumClinicalClinical TrialsCoagulation ProcessCognitiveCommunicationDataDiabetes MellitusDiffusion Magnetic Resonance ImagingDoseElderlyExcisionFDA approvedFailureFemaleFilamentGiant CellsGoalsGuidelinesHalf-LifeHemorrhageHistologicHourHumanHypertensionImmunoglobulin GInfarctionInfectionInflammationInfrastructureInterleukin 6 ReceptorInterleukin-6Ischemic StrokeLaboratoriesLinkMeasuresMechanicsMediatingMethodsModelingMotorMusNeurologic DeficitNeurological outcomeNeuroprotective AgentsOutcomeOutcome AssessmentOxidative StressPatientsPerfusionPharmaceutical PreparationsPhysiologicalPlayPreclinical TestingProcessRandomizedRattusReperfusion TherapyReproducibilityResearchResearch PersonnelRetrievalRheumatoid ArthritisRisk FactorsRodentRodent ModelRoleSafetySeveritiesStrokeSurgical suturesTestingTherapeuticTherapeutic AgentsThrombectomyThromboembolismTimeTranslationsUnited StatesUnited States National Institutes of HealthWithdrawalagedaging populationbasebrain tissueclinical riskclinically relevantcomorbiditycostcytokinedesigndisabilitydrug candidateefficacy testingfunctional outcomeshistological imagehumanized antibodyimprovedinterestmalemortalityneuroprotectionpost strokepre-clinicalpre-clinical assessmentpreservationprimary outcomereceptorrecruitsecondary outcomesexstroke incidencestroke modelstroke patientstroke therapythrombolysistocilizumab
项目摘要
Acute ischemic stroke (AIS) is the leading cause of adult disability. Reperfusion therapies are the only FDA approved treatments for AIS but are limited because of narrow therapeutic time windows. We believe a highly promising approach to develop new stroke treatments is to initiate a neuroprotective agent early after stroke onset to reduce infarct progression before, or at the time of, reperfusion therapy. Our group has found that the IL-6 receptor blocker tocilizumab, (an FDA approved medication used for rheumatoid arthritis) is profoundly neuroprotective in reducing infarct volume and improving neurological outcome in rodent models of stroke in males and females and in aged animals. The primary objective of this proposal is to determine if tocilizumab can indeed slow infarct progression and extend the therapeutic window for reperfusion therapy using IV t-PA in a highly clinically relevant thromboembolic model and in a suture model that could be applied as a surrogate of the mechanical thrombectomy (MT) (Specific Aim 2). In order to design a clinical trial to test the efficacy of thrombectomy, we will then determine if tocilizumab can extend the therapeutic window of t-PA and MT in various clinically relevant models that simulate clinical risk factors for stroke incidence and severity. These models include advanced age, hypertension, diabetes, and will examine both sexes (Specific Aim 3). Assuming we will be asked to join the Stroke Preclinical Assessment Network (SPAN) to test tocilizumab as part of the consortium effort, we will begin initial communications with the other centers recruited to SPAN to establish optimal approaches to evaluate other candidate drugs (Specific Aim 3). We will certainly be willing to participate and use our many years of expertise in translational stroke research to evaluate other treatment candidates as part of the SPAN activities.
急性缺血性中风(AIS)是成人残疾的主要原因。再灌注疗法是 FDA 唯一批准的 AIS 治疗方法,但由于治疗时间窗狭窄而受到限制。我们相信,开发新的中风治疗方法的一个非常有前途的方法是在中风发作后尽早启动神经保护剂,以在再灌注治疗之前或再灌注治疗时减少梗塞进展。我们的研究小组发现,IL-6 受体阻滞剂托珠单抗(FDA 批准的用于治疗类风湿性关节炎的药物)在雄性和雌性以及老年动物的中风啮齿动物模型中具有显着的神经保护作用,可减少梗塞体积并改善神经系统结果。该提案的主要目的是确定托珠单抗是否确实可以减缓梗塞进展并延长在临床高度相关的血栓栓塞模型和缝合模型中使用 IV t-PA 进行再灌注治疗的治疗窗,该模型可用作机械血栓切除术 (MT) 的替代品(具体目标 2)。为了设计一项临床试验来测试血栓切除术的疗效,我们将确定托珠单抗是否可以在模拟中风发病率和严重程度的临床危险因素的各种临床相关模型中延长 t-PA 和 MT 的治疗窗。这些模型包括高龄、高血压、糖尿病,并将检查两性(具体目标 3)。假设作为联盟工作的一部分,我们将被要求加入中风临床前评估网络 (SPAN) 来测试托珠单抗,我们将开始与 SPAN 招募的其他中心进行初步沟通,以建立评估其他候选药物的最佳方法(具体目标 3)。作为 SPAN 活动的一部分,我们当然愿意参与并利用我们在转化性中风研究方面多年的专业知识来评估其他候选治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jaroslaw Aronowski其他文献
Jaroslaw Aronowski的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jaroslaw Aronowski', 18)}}的其他基金
Aryl hydrocarbon receptor and bilirubin as therapeutic target for ICH
芳烃受体和胆红素作为脑出血的治疗靶点
- 批准号:
10615880 - 财政年份:2021
- 资助金额:
$ 50.69万 - 项目类别:
Aryl hydrocarbon receptor and bilirubin as therapeutic target for ICH
芳烃受体和胆红素作为脑出血的治疗靶点
- 批准号:
10299427 - 财政年份:2021
- 资助金额:
$ 50.69万 - 项目类别:
Aryl hydrocarbon receptor and bilirubin as therapeutic target for ICH
芳烃受体和胆红素作为脑出血的治疗靶点
- 批准号:
10408850 - 财政年份:2021
- 资助金额:
$ 50.69万 - 项目类别:
Optimized lactoferrin for treatment of intracerebral hemorrhage
优化乳铁蛋白治疗脑出血
- 批准号:
9016473 - 财政年份:2015
- 资助金额:
$ 50.69万 - 项目类别:
Optimized lactoferrin for treatment of intracerebral hemorrhage
优化乳铁蛋白治疗脑出血
- 批准号:
9248446 - 财政年份:2014
- 资助金额:
$ 50.69万 - 项目类别:
Optimized lactoferrin for treatment of intracerebral hemorrhage
优化乳铁蛋白治疗脑出血
- 批准号:
8831091 - 财政年份:2014
- 资助金额:
$ 50.69万 - 项目类别:
Treatment of secondary injury after ischemic stroke through targeting microglia
通过靶向小胶质细胞治疗缺血性中风后继发性损伤
- 批准号:
8573537 - 财政年份:2013
- 资助金额:
$ 50.69万 - 项目类别:
相似海外基金
Un/kindness, shame & resistance: the care of inpatients in NHS adult acute mental health units and how it might be improved
Un/善良,羞耻
- 批准号:
2885806 - 财政年份:2023
- 资助金额:
$ 50.69万 - 项目类别:
Studentship
Post-Acute Care Transitions for Older Adult Medicare Beneficiaries with Serious Mental Illness
患有严重精神疾病的老年医疗保险受益人的急性后护理过渡
- 批准号:
10772386 - 财政年份:2023
- 资助金额:
$ 50.69万 - 项目类别:
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
通过 CAR-T 细胞疗法为加拿大护理标准铺平道路:CD19 CAR-T 治疗复发/难治性成人急性淋巴细胞白血病的 II 期试验 (CLIC-01A)
- 批准号:
474619 - 财政年份:2022
- 资助金额:
$ 50.69万 - 项目类别:
Operating Grants
Investigating the impact acute inhalation of cannabis with a high content of delta-9-tetrahydrocannabinol has on myelination and microglia in adult and aged mice
研究急性吸入高含量 delta-9-四氢大麻酚的大麻对成年和老年小鼠髓鞘形成和小胶质细胞的影响
- 批准号:
485965 - 财政年份:2022
- 资助金额:
$ 50.69万 - 项目类别:
Studentship Programs
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
通过 CAR-T 细胞疗法为加拿大护理标准铺平道路:CD19 CAR-T 治疗复发/难治性成人急性淋巴细胞白血病的 II 期试验 (CLIC-01A)
- 批准号:
466358 - 财政年份:2022
- 资助金额:
$ 50.69万 - 项目类别:
Operating Grants
Metabolomics for prediction of cisplatin mediated acute kidney injury: a Canadian multi-centre adult and pediatric study
预测顺铂介导的急性肾损伤的代谢组学:加拿大多中心成人和儿童研究
- 批准号:
402040 - 财政年份:2019
- 资助金额:
$ 50.69万 - 项目类别:
Operating Grants
Study of pathogenic mechanism of age-dependent chromosome translocation in adult acute lymphoblastic leukemia
成人急性淋巴细胞白血病年龄依赖性染色体易位发病机制研究
- 批准号:
18K16103 - 财政年份:2018
- 资助金额:
$ 50.69万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Causal effect of time-varying driving pressures on mortality in mechanically ventilated, adult patients with acute respiratory distress syndrome
时变驱动压力对机械通气成年急性呼吸窘迫综合征患者死亡率的因果影响
- 批准号:
377313 - 财政年份:2017
- 资助金额:
$ 50.69万 - 项目类别:
Studentship Programs
Role of SETBP1 in adult Ph+ acute lymphoblastic leukemia
SETBP1 在成人 Ph 急性淋巴细胞白血病中的作用
- 批准号:
9315111 - 财政年份:2016
- 资助金额:
$ 50.69万 - 项目类别:
Acute Inhibition of Adult-born Granule Cells and its Effect on Antidepressant Act
成体颗粒细胞的急性抑制及其抗抑郁作用
- 批准号:
8734273 - 财政年份:2013
- 资助金额:
$ 50.69万 - 项目类别:














{{item.name}}会员




